ECO Animal Health Group (LON:EAH) Shares Cross Above Fifty Day Moving Average – Here’s What Happened

ECO Animal Health Group plc (LON:EAH) passed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of GBX 106.77 and traded as high as GBX 108.17. ECO Animal Health Group shares last traded at GBX 103, with a volume of 94,318 shares.

Analyst Ratings Changes

Separately, Shore Capital Group increased their price target on shares of ECO Animal Health Group from GBX 150 to GBX 160 and gave the stock a “buy” rating in a report on Tuesday, December 2nd. One investment analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of GBX 160.

ECO Animal Health Group Price Performance

The company has a current ratio of 2.96, a quick ratio of 2.14 and a debt-to-equity ratio of 4.81. The business has a fifty day moving average price of GBX 106.77 and a 200-day moving average price of GBX 92.97. The stock has a market capitalization of £69.10 million, a PE ratio of 23.46 and a beta of -0.05.

ECO Animal Health Group (LON:EAH) last posted its quarterly earnings results on Monday, December 1st. The company reported GBX (0.54) EPS for the quarter. ECO Animal Health Group had a return on equity of 1.27% and a net margin of 1.17%.

Insider Activity at ECO Animal Health Group

In other news, insider David Hallas bought 18,348 shares of the firm’s stock in a transaction that occurred on Thursday, December 4th. The shares were bought at an average cost of GBX 109 per share, with a total value of £19,999.32. 11.17% of the stock is currently owned by insiders.

ECO Animal Health Group Company Profile

ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.

Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.

Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry.